Pfizer, BioNTech Plan Filing After Vaccine Proves 95% Effective

Pfizer Vaccine
The coronavirus vaccine developed by Pfizer and BioNTech appears to protect 94% of adults over 65 years old.

Pfizer and BioNTech are set to apply for authorization for emergency use of their coronavirus vaccine in the U.S., BBC reported.

The firm released additional data from their ongoing phase three trials. They said the vaccine appears to protect 94% of adults over 65 years old. Data also suggests that the  works equally well in people of all ages, races and ethnicities.

The findings are based on two doses given to more than 41,000 people around the world.

Last week, Pfizer and BioNTech released preliminary data showing their vaccine  vaccine offered 90% protection against Covid-19. There were also no safety concerns.

Shortly after that, U.S. company Moderna, published results of their vaccine which claimed to have early 95% protection.

The latest data from Pfizer and BioNTech suggests the vaccine is 95% effective based on 170 cases of Covid-19 developing in volunteers. The vaccine was administered to eight participants.

Reports also said the Pfizer vaccine is being tested on people at 150 sites in the U.S., Germany, Turkey, South Africa, Brazil and Argentina.